PubRank

Jee-Fu Huang

Author PubWeight™ 73.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 2013 2.84
2 Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008 1.82
3 Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011 1.68
4 Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008 1.64
5 A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2006 1.59
6 Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 2010 1.54
7 Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. J Clin Virol 2013 1.45
8 Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010 1.34
9 The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int 2011 1.33
10 CT evaluation of gastrointestinal tract perforation. Clin Imaging 2004 1.27
11 Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2011 1.18
12 Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009 1.13
13 The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C. Gut 2007 1.10
14 Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2005 1.09
15 The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut 2007 1.08
16 Intestinal parasitic infection detected by stool examination in foreign laborers in Kaohsiung. Kaohsiung J Med Sci 2010 1.06
17 Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci 2010 1.02
18 Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res 2011 1.00
19 Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol 2009 0.98
20 Imaging of transmural migration of a retained surgical sponge: a case report. Kaohsiung J Med Sci 2004 0.98
21 Selenium, iron, copper, and zinc levels and copper-to-zinc ratios in serum of patients at different stages of viral hepatic diseases. Biol Trace Elem Res 2006 0.96
22 Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2015 0.92
23 HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010 0.90
24 Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan. Jpn J Infect Dis 2007 0.89
25 Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. Hepatol Int 2010 0.87
26 Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther 2006 0.87
27 Cirrhosis as a risk factor for tuberculosis infection--a nationwide longitudinal study in Taiwan. Am J Epidemiol 2014 0.87
28 Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. PLoS One 2012 0.86
29 Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res 2007 0.85
30 Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore) 2015 0.84
31 Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother 2013 0.83
32 Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. J Gastroenterol Hepatol 2013 0.83
33 HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study. Prev Med 2009 0.83
34 Association between transforming growth factor-beta 1 polymorphism and virologic characteristics of chronic hepatitis C. Transl Res 2008 0.82
35 Performance characteristics of a combined hepatitis C virus core antigen and anti-hepatitis C virus antibody test in different patient groups. Kaohsiung J Med Sci 2011 0.82
36 Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection. J Gastroenterol Hepatol 2014 0.82
37 Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. Scand J Infect Dis 2009 0.82
38 Long-term effects of interferon-based therapy for chronic hepatitis C. Oncology 2007 0.82
39 Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int 2010 0.82
40 Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS One 2013 0.82
41 Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Medicine (Baltimore) 2016 0.81
42 Abnormal liver function test predicts type 2 diabetes: a community-based prospective study: response to Cho et al. Diabetes Care 2008 0.81
43 Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. Hepatology 2011 0.81
44 Comparison of clinical application of the Abbott HBV PCR kit and the VERSANT HBV DNA 3.0 test to measure serum hepatitis B virus DNA in Taiwanese patients. Kaohsiung J Med Sci 2009 0.81
45 SEN and hepatitis virus infections in nontransfused children and pediatric thalassemia patients with multiple transfusions in Taiwan. Digestion 2007 0.81
46 Hepatitis C virus infection among children in aboriginal areas in Taiwan. Trans R Soc Trop Med Hyg 2008 0.80
47 A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res 2004 0.79
48 Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res 2009 0.79
49 Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One 2011 0.79
50 Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors. Clin Ther 2006 0.79
51 Outcome assessment in acute pancreatitis patients. Kaohsiung J Med Sci 2013 0.79
52 Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. Trans R Soc Trop Med Hyg 2008 0.78
53 Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. BMC Med Genet 2013 0.78
54 Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. Transl Res 2011 0.78
55 Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. Kaohsiung J Med Sci 2012 0.78
56 Hepatitis B e antigen-negative patients with persistently normal alanine aminotransferase levels and hepatitis B virus DNA > 2000 IU/mL. Hepatology 2009 0.78
57 Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study. Medicine (Baltimore) 2015 0.77
58 A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Liver Int 2006 0.77
59 Outcome of patients suffering from a spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure and treated with antivirals. Hepatology 2011 0.77
60 Early response to lamivudine therapy in clinically non-cirrhotic chronic hepatitis B patients with decompensation. Liver Int 2007 0.77
61 Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients. Medicine (Baltimore) 2016 0.76
62 Hepatitis B virus genotyping by enzyme-linked immunosorbent assay in Taiwan. Hepatol Int 2010 0.76
63 Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Hepatology 2008 0.76
64 Association between gallbladder stones and chronic hepatitis C: ultrasonographic survey in a hepatitis C and B hyperendemic township in Taiwan. Kaohsiung J Med Sci 2013 0.76
65 Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure. Hepatology 2008 0.75
66 Prevention of donor to recipient transmission of HCV in stem cell transplantation: some issues. Am J Gastroenterol 2007 0.75
67 Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues. Hepatology 2008 0.75
68 The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009 0.75
69 Revisit of oral glucose tolerance test: a must for diagnosis of type 2 diabetes in patients with chronic hepatitis C. Am J Gastroenterol 2008 0.75
70 Unveiling glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol 2009 0.75
71 A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration. Hepatology 2009 0.75
72 High serum uric acid as a novel risk factor for type 2 diabetes: response to Dehghan et al. Diabetes Care 2008 0.75
73 Links between triglyceride levels, hepatitis C virus infection and diabetes. Gut 2007 0.75
74 Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story. Hepatology 2011 0.75
75 What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivity. J Hepatol 2008 0.75
76 Insurance status and treatment candidacy of patients with hepatitis C: Taiwanese patients are luckier. Hepatology 2011 0.75
77 Possible determinants of rapid virological response suggesting shorter courses of combination therapy for hepatitis C virus genotype 2. Hepatology 2008 0.75
78 Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns. Hepatology 2009 0.75
79 Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection. Gut 2010 0.75
80 Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0. Kaohsiung J Med Sci 2007 0.75
81 Hepatocellular carcinoma associated with liver abscess. Kaohsiung J Med Sci 2009 0.75
82 Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore) 2017 0.75
83 Tarry stool in a man with acute pancreatitis. Gastroenterology 2012 0.75
84 Hepatitis C virus genotype 2/3 patients who can receive an abbreviated course of peginterferon/ribavirin: the important role of initial ribavirin doses. Hepatology 2010 0.75
85 Clinical characteristics and distribution of genotypes of TT virus infection in a hepatitis C virus-hyperendemic township of a hepatitis B virus-endemic country (Taiwan). J Gastroenterol Hepatol 2002 0.75